» Articles » PMID: 37574043

Preconditioning of Radiotherapy Enhances Efficacy of B7-H3-CAR-T in Treating Solid Tumor Models

Overview
Journal Life Sci
Publisher Elsevier
Date 2023 Aug 13
PMID 37574043
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Limited efficacy of chimeric antigen receptor T (CAR-T) cells in treating solid tumors is largely due to the antigen heterogeneity and immunosuppressive tumor microenvironment (TME). B7-H3 is over-expressed in most kind of solid tumors, making it a promising target for cancer treatment. This study aims to explore the effect of B7-H3-CAR-T therapy combined with radiotherapy in treating solid tumor models.

Methods: Irradiated tumor cell lines were prepared and tested. A humanized B7-H3-CAR-T was constructed, and it was evaluated that B7-H3-CAR-T cytotoxicity against solid tumor models with preconditioning of radiotherapy in vitro and vivo.

Results: Irradiation was found to increase expression level of B7-H3 in pancreatic cancer (PANC-1), colorectal cancer (HCT-15, SW620), acute myelocytic leukemia (AML-5), epidermoid carcinoma (KB) and glioma (U87-MG) human cell lines significantly. 6Gy irradiation was also found to up-regulate tumor-infiltration molecule like intracellular adhesion molecule-1 ICAM-1 or FAS in HCT-15 cells, supporting a possible synergistic enhancement effect of radiotherapy. In vitro and in vivo experiments demonstrated that irradiation indeed significantly enhanced the ability of B7-H3-CAR-T to infiltrate and kill tumors. Interestingly in dual-tumor mouse model study, not only tumor cells on irradiation side were eradicated completely, irradiation also enhanced CAR-T tumor-killing ability on non-irradiated side, confirming the abscopal effect of irradiation existed with CAR-T therapy.

Conclusions: Our results suggest that B7-H3-CAR-T therapy combined with radiotherapy may be a promising modality in treating solid tumors.

Citing Articles

Mixed radiation with different doses induces CCL17 to recruit CD8T cell to exert anti-tumor effects in non-small cell lung cancer.

Huang L, Wang D, Xu M, Qian D, Cao Y, Wu X Front Immunol. 2025; 15:1508007.

PMID: 39877375 PMC: 11772420. DOI: 10.3389/fimmu.2024.1508007.


Advances in CAR-T therapy for central nervous system tumors.

Zhou D, Zhu X, Xiao Y Biomark Res. 2024; 12(1):132.

PMID: 39506843 PMC: 11539471. DOI: 10.1186/s40364-024-00679-6.


Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells.

Ahmed E, Cutmore L, Marshall J Cancers (Basel). 2024; 16(18).

PMID: 39335157 PMC: 11430534. DOI: 10.3390/cancers16183186.


Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy.

Xia X, Yang Z, Lu Q, Liu Z, Wang L, Du J Mol Cancer. 2024; 23(1):175.

PMID: 39187850 PMC: 11346058. DOI: 10.1186/s12943-024-02079-8.


Strategies to overcome tumor microenvironment immunosuppressive effect on the functioning of CAR-T cells in high-grade glioma.

Zarychta J, Kowalczyk A, Marszolek A, Zawitkowska J, Lejman M Ther Adv Med Oncol. 2024; 16:17588359241266140.

PMID: 39156126 PMC: 11327996. DOI: 10.1177/17588359241266140.